Deadline Alert: Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Fractyl Health (GUTS) faces a class action securities fraud lawsuit after disclosing disappointing six-month efficacy data for its Revita treatment on January 29, 2026. The company's weight loss results (4.5% regain vs. 7.5% in control) fell significantly short of investor expectations, causing the stock to plummet 68% to $0.58 per share. Shareholders are urged to file lead plaintiff motions by October 20, 2026, with allegations that defendants made materially false statements about Revita's effectiveness and clinical prospects.